Economic evaluation of the Target-D platform to match depression management to severity prognosis in primary care: A within-trial cost-utility analysis.

Yong Yi LeeCathrine MihalopoulosMary Lou ChattertonSusan L FletcherPatty ChondrosKonstancja Densley Elizabeth MurrayChristopher DowrickAmy CoeKelsey L HegartySandra K DavidsonCaroline WachtlerVictoria J PalmerJane M Gunn

Published in: PloS one (2022)

Target-D is likely to represent good value for money for health care decision makers. Further evaluation of QALY outcomes should accompany any routine roll-out to assess comparability of results to those observed in the trial. This trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12616000537459).

Keyphrases

clinical trial
phase iii
phase ii
primary care
study protocol
healthcare
open label
depressive symptoms
randomized controlled trial
high throughput
clinical practice
type diabetes
adipose tissue
skeletal muscle
sleep quality
placebo controlled
data analysis